Nurix Therapeutics, Inc. Common stock

NRIXNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
22.60 USD
↘ 0.28 (1.22%)AT CLOSE (03:59 PM EDT)
22.74
↗ 0.13 (0.60%)
POST MARKET (AS OF 04:45 PM EDT)
Post Market
AS OF 04:45 PM EDT
22.74
↗ 0.13 (0.60%)
🟢Market: OPEN

NRIX is currently priced at $22.74. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, NRIX is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Oct 6, 2026.

Open?$23.06
High?$23.06
Low?$22.10
Prev. Close?$22.88
Volume?1.0M
Avg. Volume?1.4M
VWAP?$22.56
Rel. Volume?0.73x
Bid / Ask
Bid?$17.51 × 100
Ask?$26.79 × 100
Spread?$9.28
Midpoint?$22.15
Valuation & Ratios
Market Cap?2.4B
Shares Out?103.8M
Float?98.2M
Float %?94.6%
P/E Ratio?N/A
P/B Ratio?5.90
EPS?-$3.29
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage PlatformsAI & Machine Learning›AI Platforms & Infrastructure
Employees
357
Market Cap
2.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.nurixtx.com
Listed
2020-07-24
Address
1600 SIERRA POINT PKWY
BRISBANE, CA 94005
Phone: (415) 660-5320
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?6.34Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.31%High
Short Interest?18.0M
Days to Cover?14.1
Free Float98.2M
Avg Daily Volume1.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?6.34Strong
Quick Ratio?6.34Strong
Cash Ratio?0.94Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
31
5.90FAIR▾
P/S?
Peers
100
S&P
3
64.58HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
62.74HIGH▾
Returns & Efficiency
ROE?
S&P
3
-84.8%WEAK▾
ROA?
S&P
3
-63.7%WEAK▾
Cash Flow & Enterprise
FCF?$-304527000
Enterprise Value?$2.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist